drugset
drugset / Trial / NCT02101580

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

NCT02101580 ↗

Phase 1 Completed 21 enrolled Polaris Group
NaSingle-groupOpen-labelTreatment

Summary

Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.

Timeline

Start
2014-11-17
Primary completion
2017-05-05
Completion
2017-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegargiminase Protein / enzyme biologic — —

Indications

pancreatic neoplasm